Adakras (Adagrasib 200mg)

ADAKRAS (adagrasib 200 mg) is an inhibitor of the RAS GTPase family, approved for the following indications:

Non-Small Cell Lung Cancer (NSCLC):

• As a monotherapy for adult patients with KRAS G12C-mutated, locally advanced or metastatic NSCLC, as identified by an FDA-approved test, who have previously received at least one systemic therapy.

Colorectal Cancer (CRC):

• In combination with cetuximab for adult patients with KRAS G12C-mutated, locally advanced or metastatic CRC, as identified by an FDA-approved test, who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

*These indications have been granted accelerated approval based on objective response rate (ORR) and duration of response (DOR). Continued approval may depend on the confirmation and further characterization of clinical benefit in ongoing confirmatory trials.

adagrasib dosage

Recommended dosage as a single agent for NSCLC and in combination with cetuximab for CRC: 600 mg orally twice daily.

 • Swallow tablets whole with or without food.

Adagrasib 200mg cost price

Adagrasib price per pill from India online pharmacy is only 3% of

adagrasib cost in US. 

Adagrasib side effects:

ADAKRAS (ADAGRASIB 200MG) can cause serious side effects, including: ● Stomach and intestinal (gastrointestinal) problems. Stomach and intestinal side effects including nausea, diarrhea, or vomiting, are common with ADAKRAS (ADAGRASIB 200MG) but can also sometimes be severe. ADAKRAS (ADAGRASIB 200MG) can also cause serious stomach and intestinal side effects such as bleeding, obstruction, inflammation of the colon (colitis), and narrowing (stenosis). ○ Call your healthcare provider if you develop any of the signs or symptoms of stomach or intestinal problems listed above during treatment with ADAKRAS (ADAGRASIB 200MG). ○ Your healthcare provider may prescribe an antidiarrheal medicine or anti-nausea medicine, or other treatment, as needed.

● Changes in the electrical activity of your heart called QTc prolongation. Certain changes can occur in the electrical activity of your heart during treatment with ADAKRAS (ADAGRASIB 200MG) and can be seen on a test called an electrocardiogram (ECG or EKG). QTc prolongation can increase your risk for irregular heartbeats that can be life-threatening, such as torsades de pointes, and can lead to sudden death. ○ You should not take ADAKRAS (ADAGRASIB 200MG) if you have congenital long QT syndrome or if you currently have QTc prolongation. See “Before taking ADAKRAS (ADAGRASIB 200MG), tell your healthcare provider about all of your medical conditions, including if you:” ▪ Your healthcare provider should monitor the electrical activity of your heart and the levels of body salts in your blood (electrolytes) especially potassium and magnesium before starting and during treatment with ADAKRAS (ADAGRASIB 200MG) if you have heart failure, a slow heart rate, abnormal levels of electrolytes in your blood, or if you take a medicine that can prolong the QT interval of your heartbeat. ▪ Tell your healthcare provider if you feel dizzy, lightheaded, or faint, or if you get abnormal heartbeats during treatment with ADAKRAS (ADAGRASIB 200MG). ● Liver problems. Abnormal liver blood test results are common with ADAKRAS (ADAGRASIB 200MG) and can sometimes be severe. Your healthcare provider should do blood tests before starting and during treatment with ADAKRAS (ADAGRASIB 200MG) to check your liver function. Tell your healthcare provider right away if you develop any signs or symptoms of liver problems, including: ○ your skin or the white part of your eyes turns yellow (jaundice) ○ nausea or vomiting ○ bleeding or bruising ○ loss of appetite ○ pain, aching or tenderness on the right side of your stomach area (abdomen) ○ dark or “tea-colored” urine ○ light-colored stools (bowel movements) ○ tiredness or weakness ● Lung or breathing problems. ADAKRAS (ADAGRASIB 200MG) may cause inflammation of the lungs that can lead to death. Tell your healthcare provider or get emergency medical help right away if you have new or worsening shortness of breath, cough, or fever.

Adagrasib PI

For more Prescribing information，please ask for “FDA Prescribing Information” from our customer service.